The treatment outcome of chronic HBV infection among HBV/HIV co-infected and HBV mono-infected patients

摘要

The aim of this study was to analyze the treatment response of hepatitis B virus (HBV) to lamivudine and tenofovir disoproxil fumarate in HBV/HIV co-infected patients in comparison to HBV mono-infected patients. This study was conducted at the University Hospital for Infectious and Tropical Diseases in Belgrade from January 2000 until December 2017 and included all patients with chronic hepatitis B who received antiviral therapy. All patients initially treated with lamivudine were switched to tenofovir if lamivudine failure occurred. A patient was considered to have achieved a full treatment response if the level of HBV DNA was lower than 20 IU/ml or undetectable. HBs and HBe antigen loss and HBs seroconversion were also monitored. After a mean duration of lamivudine-containing antiretroviral therapy (ART) of 4.87 +/- 3.48 years and lamivudine mono-therapy of 4 +/- 2.52 years, failure was recorded in 82.1% and 79.3% of patients, respectively. HBV viral loads were 20 +/- 32 IU/ml and 3 +/- 13 IU/ml after 2.49 +/- 1.56 years of tenofovir-containing ART and 1.9 +/- 1.13 years of tenofovir mono-therapy, respectively. Overall mean treatment duration, taking both lamivudine- and tenofovir-based regimens into account, was 4.18 +/- 2.72 and 6.17 +/- 3.63 years in the mono- and co-infected patients, respectively (p = 0.02).